Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heine H Hansen

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Current Oncology Reports|February 2, 2002
Lung cancer--a changing pictureHeine H Hansen
BMJ (Clinical Research Ed.)|August 31, 2002
Treatment of advanced non-small cell lung cancerHeine H Hansen
Acta Oncologica (Stockholm, Sweden)|January 28, 2003
An update on management of lung cancer--Acta Oncologica Lecture-Västerås 21 March 2002Heine H Hansen
Cancer|October 5, 2002
Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinomaBo Gronlund, Heine H Hansen, Claus Høgdall, et al.
Cancer|April 5, 2002
Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinomaBo Gronlund, Claus Høgdall, Heine H Hansen, et al.
Lung Cancer (Amsterdam, Netherlands)|July 26, 2002
Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-based study in DenmarkHalla Skuladottir, Fred R Hirsch, Heine H Hansen, et al.
Gynecologic Oncology|August 7, 2004
Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with Paclitaxel-Platinum?Bo Gronlund, Claus Høgdall, Ib J Christensen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 3, 2004
Recommendations for a global core curriculum in medical oncologyHeine H Hansen, Dean F Bajorin, Hyman B Muss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2004
Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?Bo Gronlund, Claus Høgdall, Jørgen Hilden, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|May 18, 2005
Recurrent epithelial ovarian cancer: validation and improvement of an established prognostic indexBo Gronlund, Ib J Christensen, Anne Lene Bülow-Lehnsby, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Current Oncology Reports|February 2, 2002
Lung cancer--a changing pictureHeine H Hansen
BMJ (Clinical Research Ed.)|August 31, 2002
Treatment of advanced non-small cell lung cancerHeine H Hansen
Acta Oncologica (Stockholm, Sweden)|January 28, 2003
An update on management of lung cancer--Acta Oncologica Lecture-Västerås 21 March 2002Heine H Hansen
Cancer|October 5, 2002
Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinomaBo Gronlund, Heine H Hansen, Claus Høgdall, et al.
Cancer|April 5, 2002
Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinomaBo Gronlund, Claus Høgdall, Heine H Hansen, et al.
Lung Cancer (Amsterdam, Netherlands)|July 26, 2002
Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-based study in DenmarkHalla Skuladottir, Fred R Hirsch, Heine H Hansen, et al.
Gynecologic Oncology|August 7, 2004
Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with Paclitaxel-Platinum?Bo Gronlund, Claus Høgdall, Ib J Christensen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 3, 2004
Recommendations for a global core curriculum in medical oncologyHeine H Hansen, Dean F Bajorin, Hyman B Muss, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2004
Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?Bo Gronlund, Claus Høgdall, Jørgen Hilden, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|May 18, 2005
Recurrent epithelial ovarian cancer: validation and improvement of an established prognostic indexBo Gronlund, Ib J Christensen, Anne Lene Bülow-Lehnsby, et al.
Pageof 2